Patients who have rickets experience a softening and weakening of their bones traced to a vitamin deficiency. In a rare, inherited form of the disease, vitamin D supplements don’t work.
Ultragenyx (NASDAQ: RARE) has received FDA approval for a drug to treat patients who have this form of the disease, called X-linked hypophosphatemia (XLH).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,